Best Life Sciences Companies in Manchester, United Kingdom
The 59 best Life Sciences companies in Manchester, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: F2g.
Our analysis of 62 Life Sciences companies
$9.8b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2026.
Ranked: Best Life Sciences companies in Manchester
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | F2g Developer of therapeutic treatments for rare and life threatening infections 64Fin. health top 22%Funding top 23%Moat top 26%Growth top 28% All 11 signals ▾Fin. healthtop 22% Fundingtop 23% Moattop 26% Growthtop 28% Patentstop 38% Markettop 45% Innovationtop 46% Talentbottom 49% Globalbottom 47% Techbottom 28% Newsbottom 22% Fin. health: Revenue ~$101M Funding: Raised $353M across 12 rounds · 12 rounds over 24 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $353M | 21 mo ago | 27 | Francesco Lavino CEO | Series H | 142 patents Antifungal heterocyclic drug compounds and their pharmaceutical formulations. | — |
| 2 | Oxyrane Enzyme replacement therapies (ERT) to treat lysosomal storage diseases. | $76M | 109 mo ago | 3 | Charles Iii Co-Founder | Series D | 142 patents Enzyme-based glycan de‑mannosylation and lysosomal enzyme production for therapeutic targeting | — |
| 3 | Phagenesis Developer of medical devices for the treatment of Neurogenic dysphagia | $62M | 28 mo ago | 22 | Conor Mulrooney Co-Founder & COO | Acquired | 126 patents Bioelectronic therapeutic devices and wearable medical accessories for neuromodulation and dysphagia treatment | — |
| 4 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 30 mo ago | 46 | — | Public | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 5 | Yourgene Health Provider of non-invasive prenatal genetic tests and genomic services | $15M | 86 mo ago | 253 253 → 169 (-33%) | — | Public | — | — |
| 6 | Intercytex Developer of cell-based therapies for the repair and regeneration of skin and hair | $13M | 251 mo ago | 1 | Paul Kemp Founder & CEO | Series A | 48 patents Regenerative skin and hair therapies using cultured fibroblasts and hair‑inductive cells | — |
| 7 | NeuTec Pharma Developer of recombinant antibody therapies for infectious diseases | $12M | 338 mo ago | 20 | Ruth Christine Matthews Founder & COO | Acquired | 105 patents HSP90‑targeted therapeutics and antibody treatments for fungal, bacterial, and cancer diseases | — |
| 8 | Genedrive Provider of point of care molecular diagnostics platform for genotyping and sequence analysis | $9M | 15 mo ago | 43 43 → 45 (+5%) | Christopher Potten Co-Founder | Public | — | 1 partnership |
| 9 | Biorelate Developer of an artificial intelligence platform for biomedical literature curation and knowledge graph… | $9M | 43 mo ago | 23 23 → 36 (+57%) | Daniel Jamieson Founder & CEO | Series A | — | 2 job openings |
| 10 | Proveca Provider of drugs for treating chronic diseases in children | $8M | 111 mo ago | 23 | — | Series A | — | — |
| 11 | Functional Gut Group Developer of a diagnostic test for gut health | $7M | 15 mo ago | 8 | Anthony Hobson Founder | Acquired | — | — |
| 12 | Epistem Service provider of stem cell-based therapeutics and biomarkers | $7M | 69 mo ago | 35 | — | Acquired | 113 patents Patents concentrated in transport & manufacturing processes | — |
| 13 | Reacta Biotech Develop and manufacture oral food challenge materials | $6M | 59 mo ago | 16 | Ashley Woodcock Co-founder | Series B | 25 patents Standardized oral food challenge formulations for clinical allergy diagnosis | — |
| 14 | GEN inCode Developer of precison medicines by combining genetic and clinical data for cardiac disease monitoring | $4M | 30 mo ago | 26 26 → 47 (+81%) | — | Public | — | — |
| 15 | Imperagen Developer of enzyme engineering platform for drug development 16Talent top 28%Funding top 49%Tech bottom 44%Global bottom 29% All 5 signals ▾Talenttop 28% Fundingtop 49% Techbottom 44% Globalbottom 29% Marketbottom 17% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $4.3M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $4M | 1 mo ago | 5 | Timothy Eyes Co-Founder | Seed | — | — |
| 16 | Link Biologics Developer of therapeutics to treat inflammatory and degenerative disorders | $4M | 35 mo ago | — | Tony Day Co-Founder | Seed | — | 1 launch · 1 award |
| 17 | QV Bioelectronics Manufacturer of electrotherapy devices for treating brain tumors | $4M | 5 mo ago | 6 | Christopher Bullock Co-Founder & CTO | Series A | 25 patents Implantable bioelectronic devices for neural stimulation and monitoring | — |
| 18 | Bright Biotech Engages in recombinant antibody production | $3M | 43 mo ago | 1 | — | Series A | — | — |
| 19 | Ai2 Human protein-like substances as anti-infectives for medical devices | $3M | 174 mo ago | 3 | Curtis Dobson Founder | Deadpooled | 37 patents Antimicrobial small‑molecule therapeutics for fungal, protist and bacterial infections | — |
| 20 | LigBiowise Rapid diagnostic platform for the detection of pathogenic microorganisms | $3M | 101 mo ago | 7 | Alexander Sheppard CEO | Series A | — | — |
| 21 | Bioxydyn Provider of quantitative imaging biomarker services for pharmaceutical and clinical research | $2M | 165 mo ago | 8 | Geoff Parker Founder & CEO | Series A | 11 patents Pulmonary function measurement and oxygen‑enhanced medical imaging processing technologies. | 1 partnership |
| 22 | Chromition Developer of technology for immunofluorescence, cancer screening, and genomic testing | $1M | 85 mo ago | 7 | — | Funding Raised | 22 patents Functionalized nanoparticles for drug delivery, diagnostics, and light‑emitting optoelectronic devices | — |
| 23 | Imagen Therapeutics Provider of diagnostic tools for cancer treatments | $1M | 71 mo ago | 17 | Gareth Griffiths Co-Founder | Seed | — | — |
| 24 | Handsome A range of Orthopedic support products | $1M | 85 mo ago | 4 | — | Seed | 10 patents Orthopedic neck/back braces with integrated massage and TENS therapeutic features. | — |
| 25 | SwabTech Device for intra-operative blood recovery from swabs | $938K | 117 mo ago | 4 | Marcus Orton CEO | Deadpooled | 9 patents Automated cleaning and sterilization of reusable surgical swabs | — |
| 26 | Motac Provider of in vivo and ex vivo services to drug developers for neurological disorders | $775K | 78 mo ago | — | Alan Crossman CEO | Funding Raised | — | — |
| 27 | Plant Organelle Technologies Developer of technology for reprogramming chloroplast and mitochondrial genomes in crops 40Talent top 45%Global bottom 48%Funding bottom 37% All 3 signals ▾Talenttop 45% Globalbottom 48% Fundingbottom 37% Talent: 2 named leaders on record Global: Investors from 1 country beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 40/100 | $656K | 12 mo ago | — | Anil Day Co-Founder & Director | Funding Raised | — | — |
| 28 | Curapel Specialty pharmaceutical company developing technologies for common skin conditions | $496K | 123 mo ago | — | Neil Gibbs Founder | Seed | — | — |
| 29 | Renephra Wearable device for controlled fluid removal from skin to treat edema | $467K | 90 mo ago | 1 | — | Seed | 15 patents Microneedle-based transdermal fluid extraction and sampling devices for medical diagnostics | — |
| 30 | AQ-Trials Provider of a clinical trial management system designed for researchers | $304K | 42 mo ago | 6 | Ash Mahmud Co-Founder | Seed | — | 1 launch |
| 31 | Elucigene Provider of in vitro diagnostics for cystic fibrosis and other genetic diseases | $263K | 141 mo ago | 180 | Mark Street-Docherty CEO | Acquired | — | — |
| 32 | Spotlight Pathology Developer of AI-powered decision support tools for blood cancer diagnosis 37AI top 35%Talent top 38%Funding bottom 47%Growth bottom 42% All 7 signals ▾AItop 35% Talenttop 38% Fundingbottom 47% Growthbottom 42% Marketbottom 37% Globalbottom 29% Newsbottom 21% AI: Product described with: ai-powered, machine learning Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 37/100 | $162K | 4 mo ago | — | Richard Byers Co-Founder | Seed | — | — |
Top 12 Life Sciences companies in Manchester
#1
Seed · Manchester, England · founded 2021 · 5 employees$4.3Mraised▾
Developer of enzyme engineering platform for drug development. It offers enzyme products for the manufacture of complex drug molecules. It has applications in laboratory tools to enzyme replacement therapies and drug delivery systems.
- May 2026Seed$6.7M
- Aug 2022Seed$4.3M
#2
Series H · Manchester, England · founded 1998 · 27 employees$353.3Mraised▾
Developer of therapeutic treatments for rare and life threatening infections. Research focuses on identifying and creating pharmaceutical compounds to address fungal pathogens. These medical products aim to provide treatment options for patients affected by serious fungal conditions.
- Sep 2024Series H$100M
- Aug 2022Series E$70M
- Aug 2020Series D$60.8M
- Jan 2019Series C—
#3
Series A · Manchester, England · founded 2019 · 6 employees$3.6Mraised▾
Manufacturer of electrotherapy devices for treating brain tumors. The company's flagship product is GRACE, an implanted device that delivers electric field therapy directly to the tumour resection margins where GBM recurrence takes place.
- Jan 2026Grant (prize money)—
- Jan 2026Series A$6.1M
- Apr 2023Grant (prize money)$1.1M
- Jan 2023Seed$2.4M
#4
Public · Manchester, England · founded 2000 · 43 employees$9.3Mraised▾
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis. The company offers MT-RNR1 ID Kit, a pharmacogenetic test to prevent antibiotic induced deafness in infants, and Genedrive HCV ID Kit is used to screen for hepatitis C and COVID-19.
- Apr 2025Post IPO$1.6M
- Nov 2018Post IPO$7.7M
#5
Acquired · Manchester, England · founded 2014 · 8 employees$7.4Mraised▾
Developer of a diagnostic test for gut health. The product includes Breath testing for small intestinal bacterial overgrowth, Methane Breath CH4ECK for detecting abnormal methane levels, ZepHr is a reflux monitoring system, Motion testing for oesophageal function disorders, and Lower bowel testing for disorders of the pelvic floor. The company also has inSIGHT Ultima System and BioVIEW acquisition and analysis software.
- Apr 2025PE$7.4M
#6
Seed · Manchester, England · founded 2020$162Kraised▾
Developer of AI-powered decision support tools for blood cancer diagnosis. It offers machine learning technology that integrates with existing digital pathology infrastructure to improve pathology services. The AI software helps to minimize turnaround times, reduce pathologists’ hands-on time, and improve the objectivity of assessments. The technology detects cancer, differentiates cell types, performs automated cell counts and spatial analyses, quantifies heterogeneity, and discovers novel molecular biomarkers for patient risk stratification. It combines insights from multi-modal datasets.
- Mar 2026Seed$1.9M
- Apr 2025Seed$483.9K
- Jul 2024Seed$162K
#7
Acquired · Manchester, England · founded 2007 · 22 employees$62.1Mraised▾
Developer of medical devices for the treatment of Neurogenic dysphagia. The company has developed the Phagenyx System a neuromodulation system indicated to improve swallowing safety and efficiency to accelerate recovery from post-stroke dysphagia.
- Mar 2024Series D$42M
- May 2013Series B$17M
- May 2012Grant (prize money)$1.6M
- Sep 2010Series A$3.1M
#8
Public · Manchester, England · founded 2008 · 46 employees$43.2Mraised▾
Developer of optimized drug discovery and design services. The company has two proprietary and synergistic software platforms Taxonomy3, a human genetics analysis platform, and Conformetrix, which determines the 3D shape of drug molecules. The company's NMR technology provides templates for drug discovery and design and information for drug candidate optimization. The company's pipeline has candidates for the treatment of addiction (Oral Orexin-1 Antagonist), diabetes (oral GPR142 and GLP-1 agonists), inflammation, and oncology.
- Jan 2024Post IPO$11M
- Aug 2022Post IPO$6.9M
- Oct 2020Post IPO$914.9K
- Oct 2019Post IPO—
#9
Funding Raised · Manchester, England · founded 2023$656Kraised▾
Developer of technology for reprogramming chloroplast and mitochondrial genomes in crops. This technology introduces genes and gene edits into organelles. It allows engineering of traits with localized and high-level expression. The technology has potential applications for enhancing crop yields and resilience. It also supports sustainability with the potential for carbon savings.
- 2025Grant (prize money)$656K
#10
Public · Manchester, England · founded 2018 · 26 employees$4.5Mraised▾
GEN inCode is a developer of precision medicines by combining genetic and clinical data for cardiac disease monitoring. It provides solutions for the prevention and treatment of cardiovascular disease risk. The models are based on algorithms and machine learning which allows doctors to accurately measure and assess a patient's clinical and genetic risk.
- Dec 2023Post IPO$5.1M
- Aug 2021Post IPO$694.9K
- Jul 2020Series A$4.5M
- Jan 2020Seed$982.1K
#11
Series D · Manchester, England · founded 2006 · 3 employees$76Mraised▾
Oxyrane dedicated to the development of novel and bio-superior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Oxyrane engineers deficient /absent enzymes to improve their targeting and activity. Th company's lead product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. Develops recombinant enzyme products using a proprietary, engineered yeast expression platform.
- May 2017Series D$49.5M
- Nov 2011Series D$26.5M
#12
Series A · Manchester, England · founded 2014 · 23 employees$8.7Mraised▾
Developer of an artificial intelligence platform for biomedical literature curation and knowledge graph construction. This technology identifies and extracts cause-and-effect relationships from scientific literature to support drug discovery and biological research. The platform enables the analysis of connections between genes, diseases, and chemical entities to assist in target identification, biomarker selection, and indication expansion. By automating the processing of biomedical data, the system provides evidence-based insights for researchers and scientists.
- Nov 2022Series A$7.8M
- Feb 2019Grant (prize money)—
- Sep 2018Seed$914.6K
- Mar 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Manchester researches in biotechnology
Manchester's University of Manchester and affiliates lead optimistically in microbial metabolic engineering, bioproduction, and RNA research, with recent breakthroughs dominating and minimal concern.
- University of Manchester21
- Manchester Metropolitan University2
- Manchester College2
- Manchester University NHS Foundation Trust1
- Manchester Academic Health Science Centre1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.